Telix Pharmaceuticals Ltd
ASX:TLX

Watchlist Manager
Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd
ASX:TLX
Watchlist
Price: 13.685 AUD -2.81% Market Closed
Market Cap: 4.6B AUD

Telix Pharmaceuticals Ltd
Total Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Telix Pharmaceuticals Ltd
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
Telix Pharmaceuticals Ltd
ASX:TLX
Total Assets
AU$983.4m
CAGR 3-Years
108%
CAGR 5-Years
57%
CAGR 10-Years
N/A
Opthea Ltd
ASX:OPT
Total Assets
$56.8m
CAGR 3-Years
-2%
CAGR 5-Years
3%
CAGR 10-Years
9%
Mesoblast Ltd
ASX:MSB
Total Assets
$784.7m
CAGR 3-Years
6%
CAGR 5-Years
1%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Total Assets
$39.4B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
20%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Total Assets
AU$271.8m
CAGR 3-Years
24%
CAGR 5-Years
27%
CAGR 10-Years
35%
PYC Therapeutics Ltd
ASX:PYC
Total Assets
AU$183.3m
CAGR 3-Years
59%
CAGR 5-Years
42%
CAGR 10-Years
59%
No Stocks Found

Telix Pharmaceuticals Ltd
Glance View

Telix Pharmaceuticals Ltd. is an innovative biopharmaceutical company that has carved a niche for itself in the realm of targeted radiation therapy and imaging, primarily focusing on cancer treatment. Established with the vision of transforming the landscape of oncology, Telix develops molecularly-targeted radiation (MTR) products aimed at diagnosing and treating a range of significant unmet medical needs. The company's lead product, Illuccix, gained significant attention after securing regulatory approvals for use in imaging prostate cancer. Through strategic alliances with academic and research institutions, as well as commercial entities, Telix harnesses the power of radioisotopes to create compounds that bind to specific cancer cells, allowing for both precise imaging and treatment of malignancies. The business model of Telix hinges on a blend of research and development, regulatory acumen, and strategic commercialization. By advancing a pipeline of diagnostic and therapeutic radiopharmaceuticals, Telix aims to address the full cycle of cancer care—from early detection to personalized treatment. Revenue is primarily generated through the sale of its approved products, alongside potential milestone payments and royalties from partnerships. The commercial success of Illuccix and other pipeline candidates underscores the company's ability to effectively translate scientific research into marketable therapies, positioning Telix as a formidable player in the competitive arena of cancer diagnosis and treatment. By continuing to expand its portfolio and push the boundaries of nuclear medicine, Telix seeks to deliver life-changing therapies while driving sustainable growth.

TLX Intrinsic Value
12.436 AUD
Overvaluation 9%
Intrinsic Value
Price

See Also

What is Telix Pharmaceuticals Ltd's Total Assets?
Total Assets
983.4m AUD

Based on the financial report for Dec 31, 2024, Telix Pharmaceuticals Ltd's Total Assets amounts to 983.4m AUD.

What is Telix Pharmaceuticals Ltd's Total Assets growth rate?
Total Assets CAGR 5Y
57%

Over the last year, the Total Assets growth was 274%. The average annual Total Assets growth rates for Telix Pharmaceuticals Ltd have been 108% over the past three years , 57% over the past five years .

Back to Top